| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 37.594 | 67.390 | 178.910 | 301.013 | 284.172 | 175.018 |
| Total Income - EUR | - | - | - | - | 37.594 | 67.482 | 179.335 | 320.155 | 367.159 | 177.227 |
| Total Expenses - EUR | - | - | - | - | 3.270 | 48.348 | 135.445 | 159.819 | 279.986 | 139.808 |
| Gross Profit/Loss - EUR | - | - | - | - | 34.325 | 19.134 | 43.890 | 160.337 | 87.173 | 37.420 |
| Net Profit/Loss - EUR | - | - | - | - | 33.949 | 18.493 | 42.315 | 157.630 | 84.168 | 33.800 |
| Employees | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Pyramal Pharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 0 | 54.508 | 142.349 | 97.747 | 256.931 | 712.976 |
| Current Assets | - | - | - | - | 35.357 | 31.844 | 71.788 | 218.280 | 246.072 | 247.889 |
| Inventories | - | - | - | - | 0 | 23.284 | 33.516 | 26.102 | 192.316 | 172.201 |
| Receivables | - | - | - | - | 14.597 | 3.851 | 22.387 | 12.354 | 23.485 | 52.584 |
| Cash | - | - | - | - | 20.760 | 4.709 | 15.885 | 179.824 | 30.271 | 23.104 |
| Shareholders Funds | - | - | - | - | 33.991 | 32.363 | 73.960 | 229.184 | 312.657 | 344.709 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 1.366 | 55.483 | 141.616 | 90.642 | 205.111 | 616.306 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Pyramal Pharma S.r.l.